InspireMD Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.74next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly3.4MTarget: Guidance withdrawn due to voluntary recall of CGuard Prime 135 cm
U.S. Revenue Contribution Quarterly1.2MTarget: Expansion upon FDA approval of original CGuard delivery system
International Revenue Contribution Quarterly2.2MTarget: Continued growth in international demand for CGuard
Gross Margin (GAAP) Quarterly20.2%Target: Improvement following resolution of inventory impairment charges
Watch Items
- FDA Approval of Original CGuard Delivery System for CAS ProceduresTrigger: Anticipated in Q3 2026Action: Monitor regulatory announcements and subsequent commercial re-entry in the U.S.
- FDA Approval of CGuard Prime 80 cm for TCAR ProceduresTrigger: Anticipated in H2 2026Action: Track PMA supplement review progress and potential doubling of addressable U.S. market
- CGUARDIANS III Pivotal Study Progress for SwitchGuard NPSTrigger: First patient enrolled in June 2026Action: Follow clinical trial enrollment milestones and target U.S. commercial launch in 2027
- Redesigned CGuard Prime 135 cm Delivery System ApprovalTrigger: Anticipated in H1 2027Action: Assess engineering updates and regulatory submission timelines to address the voluntary recall
Research as of 19 Jun 2026